Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Inclusion Criteria: * Age: 18\~65 years. * Serum HBsAg or HBV DNA positive for at least 6 months. * Serum HBsAg and HBeAg are both positive, HBV DNA ≥ 20,000IU/ml at screening. * 2×ULN≤ ALT ≤10×ULN at screening (ULN=upper limit of normal). * Pregnancy tests of female patients must be negative. All patients with effective birth control measures during treatment period and 6 months after the treatment. Exclusion Criteria: * Pregnant or lactating women. * Mental disorder or physical disability. * Interferon treatment history or using nucleos(t)ide analogue for chronic hepatitis B treatment within the previous 6 months. * ANC \< 1500/mm3, or PLT \< 90,000/mm3. * Co-infection with HAV, HIV, HCV, HDV, or HEV. * Both of HBsAg and anti-HBs are positive, or both of HBeAg and anti-HBe are positive at screening. * Child-Pugh ≥ B, or other evidence of hepatitis decompensation (e.g.: prothrombin time prolonged more than 3 seconds, TBil \> 2ULN, Alb\<35g/L). * Chronic hepatitis caused by any other reason except hepatitis B. * Hepatocarcinoma or suffering from any other malignant tumor. * Not well-controlled endocrine diseases (e.g.: thyroid dysfunction, diabetes mellitus) * Significant function damage in any major organs (e.g.: heart, lung, kidney). * Other Conditions which in the opinion of the investigator precluding enrollment into the study (e.g.: poor compliance).